Linda astride the Mendocino Triple Junction
VBL Therapeutics, based in Israel, has just presented evidence
that one of its drugs (VBL-111) is useful in combating thyroid cancer,
glioblastoma – and ovarian cancer. Here
is the press release:
But that’s what I want to write about. No doubt you have read my characterization of
the savage pack of tort lawyers that feast on medical mistakes. To some extent the scene resembles a party of
woodcutters in a forest, nervously huddled around a campfire while all around
them twin eye-shaped pairs of lights blink on and off. The sound of gentle drooling is distinctly evident.
God help the axman who has to go into the
shadows to pee.
No doubt the “wolves” in this scene would prefer to be seen
as trailing a migrating herd of caribou, weeding out the old, weak and undeserving, thereby bettering caribou in particular and the world in general. Well, maybe.
As often is the case, there is some truth in both characterizations. However, there can be no doubt that wolf-scrutiny
inculcates caution. Here, for instance,
is VBL Therapeutics’ effort to cover its ass:
Forward
Looking Statements:
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the clinical development of VB-111 and its therapeutic potential and clinical results, including statements related to the Phase 3 pivotal trial for rGBM. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the clinical development of VB-111 and its therapeutic potential and clinical results, including statements related to the Phase 3 pivotal trial for rGBM. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
That should keep the wolves at bay, by God!
No comments:
Post a Comment